Lifescience-online "Vosaroxin, as a novel first-in-class anticancer quinolone derivative, has several potential advantages over anthracyclines and target-specific therapies. This paper offers a comprehensive review of these potential advantages in addition to discussing ...
Wall Street Journal (press release) "Vosaroxin, as a novel first-in-class anticancer quinolone derivative, has several potential advantages over anthracyclines and target-specific therapies. This paper offers a comprehensive review of these potential advantages in addition to discussing ... and more »
MarketWatch (press release) In the clinical trials conducted to this point, nemonoxacin have demonstrated excellent activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone -resistant MRSA as well as quinolone -resistant ... and more »
GlobeNewswire (press release) "Vosaroxin, as a novel first-in-class anticancer quinolone derivative, has several potential advantages over anthracyclines and target-specific therapies. This paper offers a comprehensive review of these potential advantages in addition to discussing ... and more »
